Literature DB >> 22470883

Ramadan fasting in patients with type 2 diabetes mellitus: Experience from a teaching hospital.

Jalees Fatima1, Ritu Karoli, Ashok Chandra, Nigar Naqvi.   

Abstract

Entities:  

Year:  2012        PMID: 22470883      PMCID: PMC3313764          DOI: 10.4103/2230-8210.93784

Source DB:  PubMed          Journal:  Indian J Endocrinol Metab        ISSN: 2230-9500


× No keyword cloud information.
Sir, We read the review article on the topic “Ramadan and fasting” by Jaleel et al.,[1] in the current issue with great interest. We would like to share our experiences of managing this cohort of patients with type 2 diabetes mellitus during Ramadan fasting. Though the safety of fasting in patients with diabetes has been well demonstrated by bulk of literature, it carries a risk of an assortment of complications. Many patients with diabetes insist on fasting against medical advice, thereby creating a challenge for themselves and physicians. We conducted a prospective observational study in which 179 patients with type 2 diabetes were enrolled, who decided to fast even after they had been explained about the associated risks. One month before the start of Ramadan, weight and blood pressure were recorded, and glucose/HbA1c, lipids, electrolytes, liver and renal function tests performed. The seriously ill or patients with severe complications (33) were excluded. At their first visit (2-4 weeks before Ramadan fasting), patients along with their family members were educated and counseled about self-care, signs and symptoms of hypo and hyperglycemia, diet and hydration, glucose monitoring and physical activity. Necessary changes in the diet and medications were done as per the recommendations.[23] Out of 146 patients,14 were on diet control, 90 on oral hypoglycemic agents (OHA) , 20 on OHA with insulin, and 22 on insulin alone. None of the patients on glibenclamide was allowed to fast. Most of the patients were on glimepiride, extended release gliclazide/glipizide with metformin, metformin alone or in combination with pioglitazone and alpha glucosidase inhibitors. These drugs were given before sunset meal and predawn meal as required. Insulin therapy was given in the form of premixed 30/70 administered twice daily, or NPH (Neutral Protamine Hagedorn) /Glargine at bedtime in conjunction with OHA. They were called for second visit during Ramadan (second half) and for third visit 2-4 weeks after Ramadan, for detailed assessment. 13/22 patients on insulin alone, 16/20 on insulin with OHA, 72/90 on OHA and all 14 on diet and exercise could complete fasting >15 days. The weight gain (range 1-2.6 kg) was recorded in 83/146 patients. Mean change in HbA1c was 0.5±0.3%, which was not statistically significant. No significant change in blood pressure, lipids or renal profile could be demonstrated. Hypoglycemia and hyperglycemia were the most frequent complications. The tolerance of fasting was good this year since it was during rainy season. There was significant increase in the number of mild symptomatic hypoglycemic events (164 events before Ramadan, 302 during Ramadan and 147 after Ramadan). None of the patients required hospitalization. The increase in hypoglycemic episodes was related to age (>60 years), good glycemic control before fasting (<8%), skipping of predawn meal and more vigilant and cautious attitude for hypoglycemia. Medical advice was ignored just because of religious reasons at certain occasions. In India, we have sizeable Muslim population with diabetes who decide to fast. Ramadan fasting can be facilitated for safer outcomes and lesser adverse events with intense education and counseling. Actually, increased awareness and education is not the only marker on which safe and successful fasting depends, it is the attitude of the patient and personal determination that help patient break, skip or continue fasting.[4]
  4 in total

Review 1.  Recommendations for management of diabetes during Ramadan.

Authors:  Monira Al-Arouj; Radhia Bouguerra; John Buse; Sherif Hafez; Mohamed Hassanein; Mahmoud Ashraf Ibrahim; Faramarz Ismail-Beigi; Imad El-Kebbi; Oussama Khatib; Suhail Kishawi; Abdulrazzaq Al-Madani; Aly A Mishal; Masoud Al-Maskari; Abdalla Ben Nakhi; Khaled Al-Rubean
Journal:  Diabetes Care       Date:  2005-09       Impact factor: 19.112

2.  Attitudinal determinants of fasting in type 2 diabetes mellitus patients during Ramadan.

Authors:  Jalees Fatim; Ritu Karoli; Ashok Chandra; Nigar Naqvi
Journal:  J Assoc Physicians India       Date:  2011-10

3.  A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study.

Authors:  Ibrahim Salti; Eric Bénard; Bruno Detournay; Monique Bianchi-Biscay; Corinne Le Brigand; Céline Voinet; Abdul Jabbar
Journal:  Diabetes Care       Date:  2004-10       Impact factor: 19.112

4.  Ramadan and diabetes: As-Saum (The fasting).

Authors:  Mohammed Abdul Jaleel; Syed Abbas Raza; Farah Naaz Fathima; Bushra Naaz Fathima Jaleel
Journal:  Indian J Endocrinol Metab       Date:  2011-10
  4 in total
  3 in total

Review 1.  Fasts, feasts and festivals in diabetes-1: Glycemic management during Hindu fasts.

Authors:  Sanjay Kalra; Sarita Bajaj; Yashdeep Gupta; Pankaj Agarwal; S K Singh; Sandeep Julka; Rajeev Chawla; Navneet Agrawal
Journal:  Indian J Endocrinol Metab       Date:  2015 Mar-Apr

Review 2.  Experience with DPP-4 inhibitors in the management of patients with type 2 diabetes fasting during Ramadan.

Authors:  Anja Schweizer; Serge Halimi; Sylvie Dejager
Journal:  Vasc Health Risk Manag       Date:  2013-12-24

3.  South Asian Consensus Guideline: Use of GLP-1 analogue therapy in diabetes during Ramadan.

Authors:  Md Faruque Pathan; Rakesh Kumar Sahay; Abdul Hamid Zargar; Syed Abbas Raza; A K Azad Khan; Nazrul Islam Siddiqui; Firoz Amin; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2012-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.